Healthcare, Technology May 16, 2022 07:20 PM (GMT+8) · EqualOcean
Shisi Pharmaceutical Group announced that lacosamide has been approved and registered by the State Drug Administration as an API for listed preparations. The group has obtained the drug production registration approval of lacosamide tablets (50mg and 100mg) from the State Drug Administration. Lacosamide can regulate the activity of sodium channels, effectively reduce sodium influx and reduce the excitability of neurons, so as to achieve the purpose of treating epilepsy. It is mainly used for single drug treatment and combined treatment of partial seizures in patients aged 4 years and above.